Clinical trials: Platelet-aggregation Inhibitors
Atherothrombosis
ASpirin vs Triflusal for Event Reduction In Atherothrombosis Secondary Prevention (ASTERIAS)
Investigation of the efficacy and safety of triflusal in comparison with aspirin in patients with stable coronary artery disease (CAD) and in those with a history of an acute non-cardioembolic ischemic stroke.
- Trial name
- ASTERIAS (NCT02616497)
- Testing
- Aspirin, Triflusal
- Where
- Greece
- Volunteers
- 1,220 people
- Sponsor
- University of Ioannina
Minor Stroke
Thrombolysis of Urokinase for Minor Stroke
This trial will enroll patients that have been diagnosed with minor stroke, which has occurred within the past 6 hours. TRUST is a prospective multicenter, randomized, blinded-endpoint study to evaluate the efficacy and safety of…
- Trial name
- TRUST (NCT04420351)
- Testing
- Urokinase thrombolysis, Aspirin;Clopidogrel
- Where
- China
- Volunteers
- 1,005 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Angina Pectoris
Comparison of Loading Strategies With Antiplatelet Drugs in Patients Undergoing Elective Coronary Intervention
Use of high loading doses of clopidogrel (antiplatelet drug) just before coronary interventions is associated with improved outcomes after coronary stenting.
- Trial name
- SASSICAIA (NCT02548611)
- Testing
- Prasugrel, Clopidogrel
- Where
- 5 sites in Germany, Hungary
- Volunteers
- 795 people
- Sponsor
- LMU Klinikum
Diabetes
Pharmacokinetics of Antiplatelet Drugs in Diabetic pAtients
Clopidogrel efficacy appears diminished in patients with type 2 diabetes (T2D) who continue to show an increased risk of adverse cardiovascular events and mortality compared to those without T2D.The aim of the first project is to…
- Trial name
- PANDDA (NCT02302508)
- Testing
- Clopidogrel, Prasugrel, Ticagrelor
- Where
- Canada
- Volunteers
- healthy volunteers welcome
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Acute Coronary Syndrome, Myocardial Infarction
Future Optimal Research and Care Evaluation
Rationale: Acute coronary syndrome (ACS) is the leading cause of death worldwide. To improve cardiovascular care, research is needed.
- Trial name
- FORCE-ACS (NCT03823547)
- Where
- 4 sites in Netherlands
- Volunteers
- 99,999 people
- Sponsor
- J.M. ten Berg
Acute Coronary Syndrome, Acute Myocardial Infarction
ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 Study for the Patients With ACS
The purpose of this study is to evaluate the safety of reducing dual antiplatelet therapy (DAPT) duration to 1 month after implantation of the everolimus-eluting cobalt-chromium stent (CoCr-EES) under the setting of acute…
- Conditions
- Acute Coronary Syndrome, Acute Myocardial Infarction, Coronary Artery Disease, Percutaneous Coronary Intervention
- Trial name
- STOPDAPT-2 ACS (NCT03462498)
- Testing
- 1-months DAPT, 12-month DAPT
- Where
- Japan
- Volunteers
- 3,008 people
- Sponsor
- Kyoto University, Graduate School of Medicine
Coronary Artery Disease, Coronary Artery Bypass Graft
Tranexamic Acid in On-pump CABG With Premature Clopidogrel Cessation
The use of platelet aggregation inhibitors, including aspirin and clopidogrel, has become a standard management strategy for patients with acute coronary syndrome.
- Trial name
- NCT01596738
- Testing
- Tranexamic Acid, Saline
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Li Lihuan
Platelet Aggregation Inhibitors, NSTEACS
Efficacy and Safety in Patients With Acute Coronary Syndrome Without ST-Segment Elevation
To evaluate the efficasy and safety of SR25990C(loading dose:300mg, maintenance dose:75mg/day) in comparison with the standard Japanese treatment(ticlopidine) in patients with acute coronary syndrome without ST-segment elevation…
- Trial name
- NCT00325390
- Testing
- clopidogrel (SR25990C)
- Where
- Japan
- Volunteers
- 800 people
- Sponsor
- Sanofi
Platelet Aggregation Inhibitors, Dual Anti-Platelet Therapy
Ticagrelor in Elderly Patients Undergoing Percutaneous Coronary Intervention
The study is an investigator-sponsored, retrospective cohort study designed to compare efficacy and safety of ticagrelor in elderly patients undergoing percutaneous coronary intervention.
- Conditions
- Platelet Aggregation Inhibitors, Dual Anti-Platelet Therapy, Aged, Percutaneous Coronary Intervention
- Trial name
- NCT04999293
- Testing
- Ticagrelor
- Where
- China
- Volunteers
- 1,505 people
- Sponsor
- The First Affiliated Hospital of Dalian Medical University
Aortic Valve Stenosis
Safety Profile Evaluation of TICagrelor Alone Compared to a Combination of Lysine Acetylsalicylate-Clopidogrel in the Context of Transcatheter Aortic Valve Implantation (TAVI)
Transcatheter Aortic Valve Implantation (TAVI) is now the method of choice to treat aortic stenosis in old and frail patients. Antiplatelet therapy must be associated for the procedure and during few weeks after implantation in…
- Trial name
- TICTAVI (NCT02817789)
- Testing
- Ticagrelor alone, Combination lysine acetylsalicylate - clopidogrel
- Where
- 5 sites in France
- Volunteers
- 50 people
- Sponsor
- University Hospital, Bordeaux
Platelet Aggregation Inhibitors
Maintenance Of aNtiplatElet Therapy in Patients With Coronary Stenting Undergoing Surgery (MONET BRIDGE)
The MONET BRIDGE study is designed to assess the use of cangrelor as a platelet-inhibiting bridge for patients who discontinue DAPT before cardiac and non cardiac surgery within 12 months from coronary stent implantation.
- Trial name
- NCT03862651
- Testing
- Cangrelor
- Volunteers
- 140 people
- Sponsor
- Ospedale Santa Croce-Carle Cuneo
Atrial Fibrillation
Multidisciplinary Team Approach to Prescribe Antithrombotic Therapy in Older People With Atrial Fibrillation
Antithrombotic drugs, which include antiplatelet and anticoagulant therapies, are used to prevent and treat many cardiovascular disorders.
- Trial name
- ANTITHROMBOTEA (NCT04932603)
- Testing
- Standard of care, with intervention of the multidisciplinary team
- Where
- France
- Volunteers
- 833 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Coronary Artery Disease, Stable Angina
Study Comparing Ticagrelor With Aspirin for Prevention of Vascular Events in Patients Undergoing CABG
The primary objective of this study ist to test the hypothesis that ticagrelor is superior to Aspirin (ASA) fort he prevention of major cardio- and cerebrovascular events (MACCE) in patients undergoing artery bypass operation.
- Conditions
- Coronary Artery Disease, Stable Angina, Acute Coronary Syndrome
- Trial name
- TiCAB (NCT01755520)
- Testing
- Ticagrelor, Aspirin
- Where
- 29 sites in Austria, Germany and 1 more
- Volunteers
- 1,893 people
- Sponsor
- Deutsches Herzzentrum Muenchen
Coronary Artery Disease
Antiplatelet Effects of Ticagrelor Versus Clopidogrel in American Indian Patients
Assess the pharmacodynamic effect of ticagrelor vs. Clopidogrel in American Indian patients with stable coronary artery disease.
- Trial name
- NCT01706510
- Testing
- Ticagrelor, Clopidogrel
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Rapid City Regional Hospital, Inc
Coronary Artery Disease
Pharmacokinetic Assessment of Simultaneous Administration of Clopidogrel and Aspirin
This is a randomized, open-label, single-dose, two-sequence, two-period crossover study to investigate the pharmacokinetics between a tablet containing 75 mg of Clopidogrel and 100 mg of Aspirin and the simultaneous…
- Trial name
- NCT01388660
- Testing
- Cloas, Plavix/Astrix
- Where
- South Korea
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Ajou University School of Medicine
Antiplatelet Drug-related Gastrointestinal Injury
Long-term MOno-Antiplatelet Drug Strategy After PerCutanEous CoronAry InterveNtion
The OCEAN (long-term mOn-antiplatelet drug strategy after perCutanEous coronANy intervention) study is the largest prospective multicenter data base to investigate the long-term incidence and prognosis of the use of agents for…
- Trial name
- RESCIND-OCEAN (NCT03725800)
- Where
- 8 sites in China
- Volunteers
- 1,000 people
- Sponsor
- Guangdong Provincial People's Hospital
Hypercholesterolemia, Thrombosis
The Inhibition of Platelet Antiaggregating Activity of Clopidogrel by Atorvastatin Detected by Erythromycin Breath Test: a Metabolic Inhibition of Hepatic Cytochrome P450-3A
The objective of this study is to determine if the action of the drug called clopidogrel, that you will start taking, will be decreased by another drug called atorvastatin, that you will also start taking.
- Trial name
- NCT00004564
- Testing
- Clopidogrel, Atorvastatin
- Where
- United States
- Sponsor
- National Center for Research Resources (NCRR)
Myocardial Ischemia, Hemorrhage
Predischarge Bundle to Minimize Negative Impact on Quality of Life of Nuisance Bleedings
A single-center, randomized trial of admitted patients with ischemic heart disease receiving percutaneous coronary intervention and stent implantation will be conducted at University Hospital of Ferrara.
- Conditions
- Myocardial Ischemia, Hemorrhage, Quality of Life, Platelet Aggregation Inhibitors
- Trial name
- BATMAN (NCT02554006)
- Testing
- good clinical practice, bundle group
- Where
- Italy
- Volunteers
- 448 people
- Sponsor
- University Hospital of Ferrara
Acute Coronary Syndrome
ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-3 Study
The purpose of this study is to explore the benefit of the prasugrel monotherapy without aspirin as compared with the 1-month dual therapy with aspirin and prasugrel in terms of reducing bleeding events after percutaneous…
- Trial name
- STOPDAPT-3 (NCT04609111)
- Testing
- No aspirin, 1-month DAPT
- Where
- Japan
- Volunteers
- 6,002 people
- Sponsor
- Kyoto University, Graduate School of Medicine
Acute Coronary Syndrome, Stroke
Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SP-8008
This is a single-centre, double-blind, randomised, placebo-controlled single oral-dose escalation study in healthy male subjects. It is planned to enrol approximately 48 subjects into up to 6 planned dose level cohorts.
- Trial name
- NCT04770194
- Testing
- SP-8008 Prototype Capsule A, SP-8008 Prototype Capsule B
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Shin Poong Pharmaceutical Co. Ltd.